Pays: Suisse
Langue: français
Source: Swissmedic (Swiss Agency for Therapeutic Products)
interferonum bêta-1b ADNr
Novartis Pharma Schweiz AG
L03AB08
interferonum beta-1b ADNr
Poudre et Solvant pour solution Injectable
Praeparatio cryodesiccata: interferonum beta-1b ADNr 300 µg corresp. 9.6 Mio U.I., albuminum humanum, mannitolum, natrii hydroxidum q.s. ad pH, acidum hydrochloricum q.s. ad pH pro vitro. Solvens: natrii chloridum corresp. natrium 2.5524 mg, aqua ad iniectabile ad solutionem pro 1.2 ml. Solutio reconstituta: interferonum beta-1b ADNr 250 µg corresp. 8 Mio U.I., albuminum humanum, mannitolum, aqua ad iniectabile ad solutionem pro 1 ml.
B
Biotechnologika
Traitement de la Sclérose en plaques
2013-06-27